These white papers are presented as a service to Inhalation’s readers. Content is provided by the companies listed. No product endorsement or preference is intended.
36 OctOber 2022 Inhalation
WHITE PAPERS
These technical articles are presented as a service to the readers of Inhalation.
Click on the link to access the full article. Content is provided by the companies listed.
No product endorsement or preference is intended.
3P Innovation
Dose very small quantities of pow-
der into blisters, capsules or direct
to devices without compacting or
stressing the API with 3P innovation's
Fill2Weight gravimetric system.
https://www.3pinnovation.com
Catalent
Emerging Trends and Opportunities in
Orally Inhaled Drug Products
Gain insight into the latest trends in
orally inhaled therapeutics, including
the market shift towards dry powder
inhaler products for manufacturers
and patients.
https://www.catalent.com
Copley
Discover Copley Scientific's online
library of whitepapers and articles;
a great resource for advancing your
inhaler testing knowledge. In one of
our latest releases, we investigate the
impact of electrostatics on the deliv-
ered dose uniformity of pMDIs.
https://www.copleyscientific.com
Experic
Webinar: Combination Drug Products:
What Lies Beneath – Risk Analysis For
Product Development
https://expericservices.com
Inhalation Sciences
More accurate preclinical data will
lead to better decisions to send
forward the promising substances,
be they biologics, generics or new
chemical entities.
https://inhalation.se
Astech
Automated sample preparation and
recovery from NGI equipment can
increase throughput and reduce vari-
ability of results. This is achievable
with the Xelox® Series of systems.
https://astechprojects.co.uk
Intertek
White Paper: IVBE Particle Charac-
terisation of Generic Mometasone
Furoate using MDRS & Laser Diffrac-
tion. Orthogonal methodologies to
assess API particles supporting IVBE
approaches for generic nasal suspen-
sion products.
https://www.intertek.com
Qualicaps
Quali-V
®
-I is the first hypromellose
capsule specially formulated to use
in DPIs, and to achieve exceptional
puncturing performance, optimal
aerosolization properties, minimal
microbial levels and reduced static
charge.
https://www.qualicaps.com
Recipharm
As sustainability and use of pro-
pellants with low global warming
potential (GWP) become factors
in pMDI development, Recipharm
explores considerations for ensuring
robust clinical and commercial manu-
facturing of next generation pMDIs.
https://www.recipharm.com
